Targeting of stabilized plasmid lipid particles to hepatocytes in vivo by means of coupled lactoferrin

J Drug Target. 2007 Nov;15(9):585-94. doi: 10.1080/10611860701502889.

Abstract

For non-viral gene delivery we prepared stabilized plasmid lipid particles (SPLPs), to which lactoferrin (LF) was coupled as a hepatocyte specific targeting ligand. LF-SPLPs and untargeted SPLPs labeled with [3H]cholesteryloleyl-ether were injected into rats. About 87% of the LF-SPLPs were eliminated from the blood within 5 min, while 80% of untargeted SPLPs were still circulating after 2 h. Fifty-two percent of the LF-SPLPs were taken up by hepatocytes, while non-parenchymal liver cells accounted for 16% of the uptake. Despite the efficient targeting of LF-SPLPs to hepatocytes and their capacity to transfect HepG2 and COS-7 cells in vitro, expression of a reporter gene was not detected in vivo. Overall, covalent coupling of LF to SPLPs leads to massive delivery in hepatocytes after systemic administration. However, these LF-SPLPs are not able to transfect these cells in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Drug Delivery Systems*
  • Hepatocytes / metabolism*
  • Humans
  • Lactoferrin / chemistry*
  • Lipids / administration & dosage*
  • Lipids / chemistry
  • Male
  • Plasmids*
  • Rats
  • Transfection

Substances

  • Lipids
  • Lactoferrin